NCT03604679View on ClinicalTrials.gov

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

September 11, 2020

Study Completion Date

September 11, 2020

Conditions
Advanced Solid Tumor
Interventions
DRUG

SyB C-0501

Specified dose on specified days

Trial Locations (2)

Unknown

Research Site, Chuo-ku, Tokyo

Research Site, Sayama

Sponsors
All Listed Sponsors
lead

SymBio Pharmaceuticals

INDUSTRY